surmount-1 tirzepatide weight loss results Was Associated with Improved Health-Related Quality of Life in Adults with Obesity or Overweight and Type 2 Diabetes: from the Phase 3 SURMOUNT-2 Trial | Diabetes Therapy SURMOUNT-1: Tirzepatide Drastically Reduces Weight
Description
It is a dual agonist that activates both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors simultaneously
This is because they only work temporarily, and results vary
Where is compounded tirzepatide produced
Changing your injection day You can change your weekly injection day as long as there are at least 72 hours (3 days) between doses
